Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

被引:23
|
作者
Karst, Sonja G. [1 ]
Lammer, Jan [1 ]
Mitsch, Christoph [1 ]
Schober, Manuela [1 ]
Mehta, Janhvi [1 ,2 ]
Scholda, Christoph [1 ]
Kundi, Michael [3 ]
Kriechbaum, Katharina [1 ]
Schmidt-Erfurth, Ursula [1 ]
机构
[1] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria
[2] Jaslok Hosp & Res Ctr, Mumbai, Maharashtra, India
[3] Med Univ Vienna, Ctr Publ Hlth, Vienna, Austria
关键词
Diabetic retinopathy; Diabetic macula edema; Ranibizumab; Triamcinolone; OCT; Fluorescein angiography; OPTICAL COHERENCE TOMOGRAPHY; FLUORESCEIN ANGIOGRAPHY; DEFERRED LASER; VISUAL-ACUITY; PATTERNS; OUTCOMES; PROMPT;
D O I
10.1007/s00417-017-3828-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. Methods Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. Results Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. Conclusions Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL.
引用
收藏
页码:49 / 58
页数:10
相关论文
共 50 条
  • [21] Predictive power of retinal layer responses to intravitreal ranibizumab treatment for diabetic macular edema
    Ebneter, Andreas
    Jain, Abhishek
    Wolf, Sebastian
    Zinkernagel, Martin Sebastian
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [22] The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment
    Nowacka, Barbara
    Kirkiewicz, Marta
    Mozolewska-Piotrowska, Katarzyna
    Lubinski, Wojciech
    DOCUMENTA OPHTHALMOLOGICA, 2016, 132 (02) : 111 - 122
  • [23] Retinal Vascular Caliber Changes after Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
    Wickremasinghe, Sanjeewa S.
    Rogers, Sophie L.
    Gillies, Mark C.
    Zhu, Meidong
    Wong, Tien Y.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (11) : 4707 - 4711
  • [24] Critical appraisal of ranibizumab in the treatment of diabetic macular edema
    Stewart, Michael W.
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 1257 - 1267
  • [25] Intravitreal triamcinolone acetonide for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
    Mihalache, Andrew
    Hatamnejad, Amin
    Patil, Nikhil S.
    Popovic, Marko M.
    Kertes, Peter J.
    Cruz-Pimentel, Miguel
    Muni, Rajeev H.
    OPHTHALMOLOGICA, 2024, 247 (01) : 19 - 29
  • [26] DIAMETER OF RETINAL VESSELS IN PATIENTS WITH DIABETIC MACULAR EDEMA IS NOT ALTERED BY INTRAVITREAL RANIBIZUMAB (LUCENTIS)
    Terai, Naim
    Haustein, Michael
    Siegel, Anastasia
    Stodtmeister, Richard
    Pillunat, Lutz E.
    Sandner, Dirk
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (07): : 1466 - 1472
  • [27] Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema
    Mori, Yuki
    Murakami, Tomoaki
    Suzuma, Kiyoshi
    Ishihara, Kenji
    Yoshitake, Shin
    Fujimoto, Masahiro
    Dodo, Yoko
    Yoshitake, Tatsuya
    Miwa, Yuko
    Tsujikawa, Akitaka
    PLOS ONE, 2017, 12 (04):
  • [28] High Dose Ranibizumab in the Treatment of Diabetic Macular Edema
    Marzette, L. A.
    Gloth, J.
    Beer, P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [29] Intravitreal application of triamcinolone in the treatment of diabetic macular edema
    Dusova, J.
    Kyprianou, G.
    Studni, J.
    Rencova, E.
    Korda, V.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (03) : 480 - 480
  • [30] Ranibizumab: A Review of Its Use in the Treatment of Diabetic Retinopathy in Patients With Diabetic Macular Edema
    Akiyode, Oluwaranti
    Dunkelly-Allen, Nikeshia
    JOURNAL OF PHARMACY TECHNOLOGY, 2016, 32 (01) : 22 - 28